-
While annual respirator fit-testing has proven to be the most controversial element of the recent federal action on TB, a new requirement for medical evaluation of employees also will affect infection control and employee health programs.
-
At least six children have died this year of invasive infections with community strains of methicillin-resistant Staphylococcus aureus (MRSA) after acquiring influenza, Hospital Infection Control has learned.
-
In a multicenter study of occupational HIV exposures, 38% of source patients had genotype mutations associated with resistance to anti-retroviral drugs. Recent antiretroviral treatment history was highly associated with resistance.
-
For unvaccinated or high-risk vaccinated patients during the influenza season, empirical oseltamivir treatment is cost-effective. For other patients, rapid diagnostic testing followed by treatment with oseltamivir is cost-effective. Empirical amantadine treatment offers a low-cost alternative if patients cannot afford oseltamivir.
-
As determined by process-of-care measurement, adverse event occurrence, and patient satisfaction, quality of care is compromised by infection control procedures.
-
The FDA has approved the first once-daily, quaternary ammonium, anticholinergic bronchodilator for the treatment of chronic obstructive pulmonary disease.
-
Risk of Adenocarcinoma in Barretts Esophagus; Long-Term Effect of Doxazosin, Finasteride, and Combination for BPH; Once Daily Valacyclovir to Reduce Herpes Transmission
-
-
Crisis response mode and rapidly emerging infections are the new normal for a public health system that has to expect new threats as part of the daily job, warned Julie Gerberding, MD, MPH, director of the Centers for Disease Control and Prevention (CDC).
-
Many questions continue to circle around the use of central venous catheter (CVC) devices. What are the demographics of their use and the practices of their insertion? How dangerous are they? What location in the hospital is CVC use most prevalent? What are ways to limit infection? Are there special considerations to treat infections, including bloodstream infections (BSI), resulting from the use of CVCs?